Who
Robert J. Gould
Director
Company insider
Files Form 4 as: Interim President & CEO, Fulcrum Therapeutics; Director, Turnstone Biologics; President & CEO, Epizyme.
In numbers
- Trades disclosed
- 123
- Buys
- 0
- Sells
- 44
- Bought
- $0
- Sold
- $18.8M
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 2 Jan 2014
- Last trade
- 30 Jun 2026
- Last filed
- 2 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 30 Jun 2026filed 2 Jul 2026 | FULC Fulcrum Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —32,000 at $0.00 | filing |
| 30 Jun 2026filed 2 Jul 2026 | FULC Fulcrum Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —32,000 at $0.00 | filing |
| 2 Feb 2026filed 4 Feb 2026 | FULC Fulcrum TherapeuticsBiotechnology | SEC FORM 4 Sold | $161K15,000 at $10.72 | filing |
| 2 Feb 2026filed 4 Feb 2026 | FULC Fulcrum TherapeuticsBiotechnology | SEC FORM 4 Sold | $161K15,000 at $10.72 | filing |
| 2 Jan 2026filed 4 Feb 2026 | FULC Fulcrum TherapeuticsBiotechnology | SEC FORM 4 Sold | $163K15,000 at $10.87 | filing |
| 2 Jan 2026filed 4 Feb 2026 | FULC Fulcrum TherapeuticsBiotechnology | SEC FORM 4 Sold | $163K15,000 at $10.87 | filing |
| 2 Jan 2026filed 6 Jan 2026 | FULC Fulcrum TherapeuticsBiotechnology | SEC FORM 4 Sold | $178K15,000 at $11.87 | filing |
| 2 Jan 2026filed 6 Jan 2026 | FULC Fulcrum TherapeuticsBiotechnology | SEC FORM 4 Sold | $178K15,000 at $11.87 | filing |
| 19 Nov 2025filed 21 Nov 2025 | FULC Fulcrum TherapeuticsBiotechnology | SEC FORM 4 Sold | $165K15,000 at $11.03 | filing |
| 26 Jun 2025filed 30 Jun 2025 | FULC Fulcrum Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —36,000 at $0.00 | filing |
| 17 Jun 2024filed 18 Jun 2024 | FULC Fulcrum Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 3 Jun 2024filed 2 Jul 2024 | Turnstone Biologicsoption or derivative | SEC FORM 4 Code A | —12,770 at $0.00 | filing |
| 27 Jun 2023filed 29 Jun 2023 | FULC Fulcrum Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 13 Jan 2023filed 13 Jan 2023 | FULC Fulcrum TherapeuticsBiotechnology | SEC FORM 4 Sold | $101K6,766 at $15.00 | filing |
| 27 Jun 2022filed 29 Jun 2022 | FULC Fulcrum Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,000 at $0.00 | filing |
| 7 Jun 2022filed 8 Jun 2022 | FULC Fulcrum Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —71,435 at $0.00 | filing |
| 7 Jun 2022filed 8 Jun 2022 | FULC Fulcrum TherapeuticsBiotechnology | SEC FORM 4 Code M | $560K71,435 at $7.84 | filing |
| 7 Jun 2022filed 8 Jun 2022 | FULC Fulcrum TherapeuticsBiotechnology | SEC FORM 4 Sold | $578K71,435 at $8.09 | filing |
| 6 Jun 2022filed 6 Jun 2022 | FULC Fulcrum Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —24,382 at $0.00 | filing |
| 6 Jun 2022filed 6 Jun 2022 | FULC Fulcrum TherapeuticsBiotechnology | SEC FORM 4 Code M | $191K24,382 at $7.84 | filing |
News
No headline names them, or the companies they trade most, lately.